CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy.

The use of leukemia cells as antigen-presenting cells (APCs) in immunotherapy is critically dependent on their capacity to initiate and sustain an antitumor-specific immune response. Previous studies suggested that pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells could be manipulated in vitro through the CD40-CD40L pathway to increase their immunostimulatory capacity. We extended the APC characterization of CD40L-activated BCP-ALL for their potential use in immunotherapy in a series of 19 patients. Engaging CD40 induced the up-regulation of CCR7 in 7 of 11 patients and then the migration to CCL19 in 2 of 5 patients. As accessory cells, CD40L-activated BCP-ALL induced a strong proliferation response of naive T lymphocytes. Leukemia cells, however, were unable to sustain proliferation over time, and T cells eventually became anergic. After CD40-activation, BCP-ALL cells released substantial amounts of interleukin-10 (IL-10) but were unable to produce bioactive IL-12 or to polarize TH1 effectors. Interestingly, adding exogenous IL-12 induced the generation of interferon-gamma (IFN-gamma)-secreting TH1 effectors and reverted the anergic profile in a secondary response. Therefore, engaging CD40 on BCP-ALL cells is insufficient for the acquisition of full functional properties of immunostimulatory APCs. These results suggest caution against the potential use of CD40L-activated BCP-ALL cells as agents for immunotherapy unless additional stimuli, such as IL-12, are provided.

[1]  M. Brown,et al.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. , 2006, Blood.

[2]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[3]  D. Neuberg,et al.  Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Kastelein,et al.  Novel IL-12 family members shed light on the orchestration of Th1 responses , 2003, Trends in Immunology.

[5]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[6]  M. Roncarolo,et al.  The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells , 2002, International Archives of Allergy and Immunology.

[7]  R. Stripecke,et al.  Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods , 2002, Leukemia.

[8]  M. Introna,et al.  CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-γ production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia , 2002, Leukemia.

[9]  M. Brenner,et al.  Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. , 2002, Blood.

[10]  R. Rabin,et al.  Human B Cells Become Highly Responsive to Macrophage-Inflammatory Protein-3α/CC Chemokine Ligand-20 After Cellular Activation Without Changes in CCR6 Expression or Ligand Binding , 2002, The Journal of Immunology.

[11]  F. Sinigaglia,et al.  Modulation of chemokine receptor expression and chemotactic responsiveness during differentiation of human naive T cells into Th1 or Th2 cells , 2002, European journal of immunology.

[12]  F. Sallusto,et al.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 , 2002, European journal of immunology.

[13]  H. Hamada,et al.  CD40 Ligand Promotes Priming of Fully Potent Antitumor CD4+ T Cells in Draining Lymph Nodes in the Presence of Apoptotic Tumor Cells , 2001, The Journal of Immunology.

[14]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[15]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[16]  M. Roncarolo,et al.  Type 1 T regulatory cells , 2001, Immunological reviews.

[17]  C. Rooney,et al.  Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. , 2001, Experimental hematology.

[18]  S. Sallan,et al.  Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. , 2001, Blood.

[19]  P. Allavena,et al.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. , 2001, The Journal of clinical investigation.

[20]  R. Hurwitz,et al.  Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. , 2001, Human gene therapy.

[21]  P. Allavena,et al.  Dendritic cells as a major source of macrophage‐derived chemokine/CCL22 in vitro and in vivo , 2001, European journal of immunology.

[22]  M. Urashima,et al.  CD40 Ligand Immunotherapy in Cancer: An Efficient Approach , 2001, Leukemia & lymphoma.

[23]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[24]  P. Allavena,et al.  Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys , 2000, Nature Immunology.

[25]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[26]  S. Sallan,et al.  Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. , 1999, Blood.

[27]  D. Olive,et al.  What is the real role of CD40 in cancer immunotherapy? , 1999, Immunology today.

[28]  E. Wolf,et al.  CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs , 1999, Cell.

[29]  G Bellone,et al.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.

[30]  J. Gribben,et al.  Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon γ, and IL-10: Role of B Cells in the Maintenance of  T Cell Responses , 1999, The Journal of experimental medicine.

[31]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[32]  R Bonecchi,et al.  Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. , 1998, Journal of immunology.

[33]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. , 1998, The Journal of clinical investigation.

[34]  P. Allavena,et al.  Adhesion, transendothelial migration, and reverse transmigration of in vitro cultured dendritic cells. , 1998, Blood.

[35]  J. Cyster,et al.  Epstein-Barr Virus–induced Molecule 1 Ligand Chemokine Is Expressed by Dendritic Cells in Lymphoid Tissues and Strongly Attracts Naive T Cells and Activated B Cells , 1998, The Journal of experimental medicine.

[36]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[37]  J. Cyster,et al.  A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[39]  P. Allavena,et al.  IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages , 1998, European journal of immunology.

[40]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[41]  H. Gadner,et al.  The Present Role of Bone Marrow and Stem Cell Transplantation in the Therapy of Children with Acute Leukemia , 1997, Annals of the New York Academy of Sciences.

[42]  J. Gribben,et al.  Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. , 1997, Blood.

[43]  J. Ceuppens,et al.  CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules , 1997, Leukemia.

[44]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[45]  J. Louis,et al.  Genetically resistant mice lacking interleukin‐12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response , 1996, European journal of immunology.

[46]  D. Carvajal,et al.  IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses , 1996 .

[47]  D. Carvajal,et al.  IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. , 1996, Immunity.

[48]  D. Carvajal,et al.  Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist , 1995, European journal of immunology.

[49]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[50]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[51]  Giorgio,et al.  Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells , 1992, The Journal of experimental medicine.

[52]  F. Behm,et al.  Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.

[53]  F. Colotta,et al.  Arachidonic acid and leukotriene B4 induce aggregation of human peripheral blood mononuclear leucocytes in vitro , 1984, British journal of haematology.

[54]  D. H. Mellor,et al.  Real time , 1981 .